165 related articles for article (PubMed ID: 25355431)
1. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents.
Swaminathan S; Mor V; Mehrotra R; Trivedi AN
Health Serv Res; 2015 Jun; 50(3):790-808. PubMed ID: 25355431
[TBL] [Abstract][Full Text] [Related]
2. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.
Wang C; Kane R; Levenson M; Kelman J; Wernecke M; Lee JY; Kozlowski S; Dekmezian C; Zhang Z; Thompson A; Smith K; Wu YT; Wei Y; Chillarige Y; Ryan Q; Worrall C; MaCurdy TE; Graham DJ
JAMA Intern Med; 2016 Dec; 176(12):1818-1825. PubMed ID: 27775769
[TBL] [Abstract][Full Text] [Related]
3. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
Charytan C
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
[TBL] [Abstract][Full Text] [Related]
4. Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
Iglehart JK
N Engl J Med; 2011 Feb; 364(7):593-5. PubMed ID: 21323538
[No Abstract] [Full Text] [Related]
5. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
6. ESA payment changes: chasing a moving target.
Sargent JA
Nephrol News Issues; 2008 Jan; 22(1):36-7. PubMed ID: 18271437
[No Abstract] [Full Text] [Related]
7. When payment systems collide: the effect of hospitalization on anemia in renal dialysis patients.
Turenne MN; Hirth RA; Messana JM; Turner JS; Sleeman KK; Wheeler JR
Med Care; 2010 Apr; 48(4):296-305. PubMed ID: 20195175
[TBL] [Abstract][Full Text] [Related]
8. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
9. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
Bhat P; Sokolowski W; Bhat JG
Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
[TBL] [Abstract][Full Text] [Related]
10. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
11. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
Yu JM; Shord SS; Cuellar S
J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
[TBL] [Abstract][Full Text] [Related]
12. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
Brookhart MA; Schneeweiss S; Avorn J; Bradbury BD; Liu J; Winkelmayer WC
JAMA; 2010 Mar; 303(9):857-64. PubMed ID: 20197532
[TBL] [Abstract][Full Text] [Related]
13. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs.
Hirth RA; Held PJ; Orzol SM; Dor A
Health Serv Res; 1999 Feb; 33(6):1567-92. PubMed ID: 10029498
[TBL] [Abstract][Full Text] [Related]
14. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
[TBL] [Abstract][Full Text] [Related]
15. Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes.
Dore DD; Swaminathan S; Gutman R; Trivedi AN; Mor V
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S42-50. PubMed ID: 23849152
[TBL] [Abstract][Full Text] [Related]
16. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
Wish JB
Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
[TBL] [Abstract][Full Text] [Related]
17. Iron replacement therapy: assessing today's options to prepare for bundling.
Yee J
Nephrol News Issues; 2010 Feb; 24(2):suppl 1-8. PubMed ID: 20333988
[TBL] [Abstract][Full Text] [Related]
18. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
19. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
[TBL] [Abstract][Full Text] [Related]
20. What can we learn from the U.S. expanded end-stage renal disease bundle?
Chambers JD; Weiner DE; Bliss SK; Neumann PJ
Health Policy; 2013 May; 110(2-3):164-71. PubMed ID: 23419419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
